Abstract
In the past, cancer development was studied in terms of genetic mutations acquired in cancer cells at each stage of the development. We present an emerging model for cancer development in which the tumor microenvironment (TME) plays an integral part. In this model, the tumor development is initiated by a slowly growing nearly homogeneous colony of cancer cells that can evade detection by the cell’s innate mechanism of immunity such as natural killer (NK) cells (first stage; colonization). Subsequently, the colony develops into a tumor filled with lymphocytes and stromal cells, releasing pro-inflammatory cytokines, growth factors, and chemokines (second stage; lymphocyte infiltration). Cancer progression proceeds to a well-vesiculated silent tumor releasing no inflammatory signal, being nearly devoid of lymphocytes (third stage; silenced). Eventually some cancer cells within a tumor undertake epithelial-to-mesenchymal transition (EMT), which leads to cancer metastasis (fourth stage; EMT). If a circulating metastasized cancer cell finds a niche in a new tissue and evades detection by NK cells, it can establish a new colony in which very few stromal cells are present (fifth stage; metastasis), which is much like a colony at the first stage of development. At every stage, cancer cells influence their own TME, and in turn, the TME influences the cancer cells contained within, either by direct interaction between cancer cells and stromal cells or through exchange of cytokines. In this article, we examine clinical findings and animal experiments pertaining to this paradigm-shifting model and consider if, indeed, some aspects of cancer development are governed solely by the TME.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Stratton MR (2011) Exploring the genomes of cancer cells: progress and promise. Science 331(March):1553–1558. https://doi.org/10.1126/science.1204040
Marcus A, Gowen BG, Thompson TW et al (2014) Recognition of tumors by innate immune system and natural killer cells. Adv Immunol 122:91–128 https://doi.org/10.1016/B978-0-12-800267-4.00003-1
Burstein HJ, Polyak K et al (2004) Ductal carcinoma in situ of the breast. N Engl J Med 350:1430–1441
Yamaguchi R, Perkins G (2018) Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration. Cancer Biol Ther 18:1–10. https://doi.org/10.1080/15384047.2018.1470722
Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74–80
Yeung KT, Yang J (2017) Epithelial–mesenchymal transition in tumor metastasis. Mol Oncol 11:28–39. https://doi.org/10.1002/1878-0261.12017
Labelle M, Begum S, Hynes RO (2011) Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590. https://doi.org/10.1016/j.ccr.2011.09.009
Hong Y, Fang F, Zhang Q (2016) Circulating tumor cell clusters: what we know and what we expect (review). Int J Oncol 49:2206–2216. https://doi.org/10.3892/ijo.2016.3747
Harlin H, Meng Y, Peterson AC et al (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69(7):3077–3086. https://doi.org/10.1158/0008-5472.CAN-08-2281
Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5(1):3–9. https://doi.org/10.1158/2326-6066.CIR-16-0297
Malladi S, Macalinao D, Jin X et al (2016) Metastatic latency and immune evasion through autocrine inhibition of WNT article metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165:45–60. https://doi.org/10.1016/j.cell.2016.02.025
Tabbekh M, Franciszkiewicz K (2018) Rescue of tumor-infiltrating lymphocytes from activation-induced cell death enhances the antitumor CTL response in CD5-deficient mice. J Immunol 187:102–109. https://doi.org/10.4049/jimmunol.1004145
Zhou R, He P, Ren Y et al (2007) Myeloid suppressor cell-associated immune dysfunction in CSA1M fibrosarcoma tumor-bearing mice. Cancer Sci 98(6):882–889. https://doi.org/10.1111/j.1349-7006.2007.00465.x
Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ (2012) Tumor-derived granulocytes-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21(6):822–835. https://doi.org/10.1016/j.ccr.2012.04.025
Pylayeva-gupta Y, Lee KE, Hajdu CH, Miller G, Bar-sagi D (2012) Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21(6):836–847. https://doi.org/10.1016/j.ccr.2012.04.024
Zhu Y, Knolhoff BL, Meyer MA et al (2014) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74:5057–5070. https://doi.org/10.1158/0008-5472.CAN-13-3723
Strachan DC, Ruffell B, Oei Y et al (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells CSF1R inhibition delays cervical and mammary tumor growth in murine models by. Oncoimmunology 2(12):e26968. https://doi.org/10.4161/onci.26968
Garcia AJ, Ruscetti M, Arenzana TL, Tran LM, Bianci-frias D, Sybert E (2017) Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor. Mol Cell Biol 34(11):2017–2028. https://doi.org/10.1128/MCB.00090-14
Pasello G, Zago G, Lunardi F et al (2018) Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor heterogeneity over time original article. Ann Oncol 29(March):1258–1265. https://doi.org/10.1093/annonc/mdy086
Fassina A, Cappellesso R, Guzzardo V et al (2011) Epithelial–mesenchymal transition in malignant mesothelioma. Mod Pathol 25(1):86–99. https://doi.org/10.1038/modpathol.2011.144
Hmeljak J, Sanchez-vega F, Hoadley KA et al (2018) Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 81(12):1548–1565. https://doi.org/10.1158/2159-8290.CD-18-0804
Mezzapelle R, Rrapaj E, Gatti E et al (2016) Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells. Sci Rep 6(February):22850. https://doi.org/10.1038/srep22850
Schwartz H, Blacher E, Amer M et al (2016) Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation. Cancer Res 76(15):4359–4372. https://doi.org/10.1158/0008-5472.CAN-16-0485
Strachan DC, Ruffell B, Oei Y et al (2013) CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2(12):e26968. https://doi.org/10.4161/onci.26968
Zhu Y, Knolhoff BL, Meyer MA et al (2014) CSF1/CSF1R blockade reprograms tumor-in filtrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 74:5057–5070. https://doi.org/10.1158/0008-5472.CAN-13-3723
Menon H, Ramapriyan R, Cushman TR et al (1933) Role of radiation therapy in modulation of the tumor stroma and microenvironment. Front Immunol 10(February):2019. https://doi.org/10.3389/fimmu.2019.00193
Bernstein MB, Krishnan S, Hodge JW, Chang JY (2016) Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 13(8):516–524. https://doi.org/10.1038/nrclinonc.2016.30
Yao ES, Zhang H, Chen Y et al (2007) Increased B1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 67(2):659–665. https://doi.org/10.1158/0008-5472.CAN-06-2768
Hu-lieskovan S, Mok S, Moreno BH et al (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma. Sci Transl Med 7(279):279ra41
Frederick DT, Piris A, Cogdill AP et al (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19(5):1225–1232. https://doi.org/10.1158/1078-0432.CCR-12-1630
Pelster MS, Amaria RN (2019) Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trials. Ther Adv Med Oncol 11:1–11. https://doi.org/10.1177/1758835919830826
Morgan A, Holmes A (1980) Concentrations and dimensions of coated and uncoated asbestos fibres in the human lung. Br J Ind Med 37:25–32
Feder IS, Tischoff I, Theile A, Schmitz I, Merget R, Tannapfel A (2017) The asbestos fibre burden in human lungs: new insights into the chrysotile debate. Eur Respir J 49:1602534. https://doi.org/10.1183/13993003.02534-2016
Boylan AM, Sanan DA, Sheppard D, Broaddus VC (1995) Vitronectin enhances internalization of crocidolite asbestos by rabbit pleural mesothelial cells via the integrin avfi5. J Cli Invest 96:1987–2001
Liu W, Ernst JD, Broaddus VC (2000) Phagocytosis of crocidolite asbestos induces oxidative stress, DNA damage, and apoptosis in mesothelial cells. Am J Respir Cell Mol Biol 23:371–378
Serio G, Pagliarulo V, Marzullo A, Punzi A, Pezzuto F (2016) Case report molecular changes of malignant mesothelioma in the testis and their impact on prognosis: analyses of two cases. Int J Clin Exp Pathol 9(7):7658–7667
Marsella JM, Liu BL, Vaslet CA, Kane AB (1997) Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. Environ Health Perspect 105(September):1069–1072
de Reynies A, Jaurand M-C, Renier A et al (2014) Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 20(5):1323–1335. https://doi.org/10.1158/1078-0432.CCR-13-2429
Chung CT, Da G, Santos C et al (2010) FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. J Clin Pathol 63:630–634. https://doi.org/10.1136/jcp.2010.076794
Sarun KH, Lee K, Williams M et al (2018) Genomic deletion of BAP1 and CDKN2A are useful markers for quality control of malignant pleural mesothelioma (MPM) primary cultures. Int J Mol Sci 19:3056. https://doi.org/10.3390/ijms19103056
Hylebos M, Van Camp G, Van Meerbeeck JP (2016) The genetic landscape of malignant pleural mesothelioma: results from massively parallel sequencing. J Thorac Oncol 11(10):1615–1626. https://doi.org/10.1016/j.jtho.2016.05.020
Yamaguchi R, Perkins G (2012) Finding a panacea among combination cancer therapies. Cancer Res 72(1):18–23. https://doi.org/10.1158/0008-5472.CAN-11-3091
Bruno R, Alì G, Giannini R et al (2017) Malignant pleural mesothelioma and mesothelial hyperplasia: a new molecular tool for the differential diagnosis. Oncotarget 8(2):2758–2770
Parodi S, Filiberti R, Marroni P et al (2015) Differential diagnosis of pleural mesothelioma using logic learning machine. BMC Bioinformatics 16(Suppl 9):S3
Tosun AB, Yergiyev O, Kolouri S, Silverman JF, Rohde GK (2015) Detection of malignant mesothelioma using nuclear structure of mesothelial cells in effusion cytology specimens. Cytometry A 87A:326–333. https://doi.org/10.1002/cyto.a.22602
Kundu S, Kolouri S, Erickson KI, Kramer AF, Rohde GK, May CV (2018) Discovery and visualization of structural biomarkers from MRI using transport-based morphometry. Neuroimage 167:256–275. arXiv:170504919v1
Dozier J, Zheng H, Adusumilli PS (2017) Immunotherapy for malignant pleural mesothelioma: current status and future directions. Trans Lung Cancer 6(4):315–324. https://doi.org/10.21037/tlcr.2017.05.02
Milano MT, Zhang H (2010) Malignant pleural mesothelioma: a population-based study of survival. JTO Acquis 5(11):1841–1848. https://doi.org/10.1097/JTO.0b013e3181f1cf2b
Boutin C, Xey F, Gouvemet J et al (1993) Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients part 2: prognosis and staging. Cancer 72:394–404
Minnema-Luiting J, Vroman H, Aerts J, Cornelissen R (2018) Heterogeneity in immune cell content in malignant pleural mesothelioma. Int J Mol Sci 19:1041. https://doi.org/10.3390/ijms19041041
Varin E, Denoyelle C, Brotin E et al (2010) Downregulation of Bcl-x L and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy. Carcinogenesis 31(6):984–993. https://doi.org/10.1093/carcin/bgq026
Debrincat MA, Josefsson EC, James C et al (2012) Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival. Blood 119(24):5850–5858. https://doi.org/10.1182/blood-2011-12-398834
Yamaguchi R, Lartigue L, Perkins G (2019) Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Ther 195:13–20
Soini Y, Kinnula V, Kaarteenaho-wiik R, Apoptosis KE (1999) Expression of apoptosis regulating proteins bcl-2. Clin Cancer Res 5(November):3508–3515
Yamaguchi R, Perkins G, Hirota K (2015) Targeting cholesterol with beta-cyclodextrin sensitizes cancer cells for apoptosis. FEBS Lett 589:4097. https://doi.org/10.1016/j.febslet.2015.11.009
Acknowledgement
We would like to thank Prof. Courtney Broaddus at the Dept. of Medicine, University of California, San Francisco, for informative discussion on MPM. The project was initiated when R.Y. was at Kansai Medical University, Hirakata, Japan.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Yamaguchi, R., Perkins, G. (2020). An Emerging Model for Cancer Development from a Tumor Microenvironment Perspective in Mice and Humans. In: Birbrair, A. (eds) Tumor Microenvironment. Advances in Experimental Medicine and Biology, vol 1225. Springer, Cham. https://doi.org/10.1007/978-3-030-35727-6_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-35727-6_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35726-9
Online ISBN: 978-3-030-35727-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)